According to the Financial Times, Johnson & Johnson has been negotiating with two yet-to-be-named Chinese biotech companies. The move comes after J&J's successful collaboration with Chinese-founded Legend Biotech resulted in U.S. Food and Drug Administration approval for a CAR-T cancer therapy.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. The country currently conducts the most clinical trials for revolutionary cancer therapy, which engineers patients
